Skip to content
Dosage GuideResearch Reference

Uroguanylin Dosage

Research-based dosing protocols, timing guidance, and reconstitution reference for Uroguanylin. All information is for educational purposes only.

Quick Answer

In clinical trials, Uroguanylin and its analogs (like Plecanatide) are typically administered orally at doses ranging from 3-9 mg once daily for gastrointestinal conditions. These doses are based on human clinical trials focused on stimulating guanylate cyclase-C (GC-C). Actual Uroguanylin dosage may vary based on its formulation and specific indication.

→ Uroguanylin Benefits→ Uroguanylin Side Effects→ Full Uroguanylin Profile
Table of Contents

Standard Dosage Range

Research dosing range: 3-9 mg (oral)

Educational reference only

These dosage ranges are derived from preclinical research and community protocols. No human clinical dose-ranging trials have established therapeutic doses for most research peptides. Always consult a qualified healthcare provider before starting any peptide protocol.

Dosage by Use Case

Chronic Idiopathic Constipation (CIC)

3-9 mg1× daily
Duration

12 weeks

Oral administration. Plecanatide, an analog of uroguanylin, is FDA-approved for CIC at a dosage of 3 mg daily.

Irritable Bowel Syndrome with Constipation (IBS-C)

3-9 mg1× daily
Duration

12 weeks

Oral administration. Plecanatide is also approved for IBS-C at a dosage of 3 mg daily. Higher doses may be used in research settings.

Metabolic Syndrome (Experimental)

3-6 mg1× daily
Duration

8-12 weeks

Oral administration. Rationale is based on its potential to improve sodium homeostasis and appetite regulation, but clinical evidence is preliminary.

Colorectal Cancer Prevention (Experimental)

3-9 mg1× daily
Duration

Ongoing

Oral administration. Based on preclinical data suggesting uroguanylin's tumor-suppressive effects. Human trials are limited.

Timing & Frequency

Oral dosing is typically administered once daily, with or without food. Consistent timing each day may help optimize its effects on intestinal function.

Cycle Guidance

Clinical trials have used uroguanylin analogs for up to 12 weeks. Longer durations may be considered under medical supervision. Cycling is not typically required, but monitoring for any potential side effects is advised.

Reconstitution Reference

Quick reference for reconstituting Uroguanylin. For custom vial sizes and concentrations, use the Reconstitution Calculator.

Common Vial SizeN/A (Typically supplied as oral tablets)
BAC Water VolumeN/A
Concentration & DrawN/A
StorageStore oral tablets as directed by the manufacturer, typically at room temperature and protected from moisture.
StabilitySee manufacturer's specifications for stability information.
Use the Reconstitution Calculator → for precise injection volumes based on your exact vial size, water volume, and desired dose.

Frequently Asked Questions

What is the dosage of uroguanylin for constipation?
The standard dosage of Plecanatide, a uroguanylin analog, for chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C) is 3 mg orally once daily. Higher doses (up to 9 mg) have been explored in research settings.
How is uroguanylin administered?
Uroguanylin and its analogs are administered orally, typically as tablets or capsules.
Are there any known side effects of uroguanylin?
The most common side effect reported in clinical trials with Plecanatide is diarrhea. Other potential side effects include abdominal pain, nausea, and flatulence. These effects are generally mild to moderate in severity.
Can uroguanylin be used long-term?
Uroguanylin analogs have been used for up to 12 weeks in clinical trials. Long-term use should be discussed with a healthcare provider to monitor for any potential adverse effects.

Last updated: 2026-02-19